News GLP-1 drugs linked to reduced acute schizophrenia episodes The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.
News Lilly's Zepbound enhances Taltz efficacy in psoriasis study A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.
News UK watchdog takes first action on oral weight drug adverts Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.
News Lilly fleshes out triple G data in diabetes and obesity Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.
News Novo turns to Hengrui for another oral obesity drug Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
News Novo Nordisk's IL-6 drug flunks two more heart trials Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.